Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized to reach sophisticated international markets.
Mr. Mookim, could you give our international readers a brief introduction of IQVIA and explain what your drivers of success in the Indian market are?
"The clinical trials space in India is still emerging and we do think that the market will continue opening up."
